AMIVAS Launches Europe's First and Only Licensed Severe Malaria Treatment
WATERFORD, Ireland
AMIVAS Ireland Ltd (AMIVAS), a biopharmaceutical company focused on developing, commercialising, manufacturing and distributing artesunate for the treatment of severe malaria, today announced the launch of Artesunate AMIVAS in Europe and the U.K.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241017001569/en/
(Photo: Business Wire)
Artesunate AMIVAS is the first and only product licensed, manufactured in a regulated setting, and approved to treat severe malaria in the EU, European Area (EEA), and the U.K. Severe malaria is a disease that impacts an estimated 1,250 European travelers each year. Artesunate AMIVAS is sold as a 110-milligram powder and solvent combined to create an injectable solution.
Artesunate AMIVAS is now available from the Scandinavian distributor, Nordic Prime in Denmark, Finland, Sweden and Norway. To order, see https://www.nordicprime.dk/h
'The launch of Artesunate AMIVAS across Europe means that, for the first time, travelers to and from malaria-endemic regions of the world, and military personnel deployed there, now have access to a licensed, approved severe malaria treatment that could save their lives if needed, said Laura Walsh, AMIVAS Operations Director. 'Because of the well-established safety and efficacy profile of Artesunate AMIVAS, healthcare practitioners can now be confident when treating an adult or child diagnosed with severe malaria.'
'It is gratifying to be launching Artesunate AMIVAS in Europe after its successful launch in the United States,' said Sean Power, AMIVAS Director, Ireland. 'The AMIVAS mission is focused on bringing safe, effective, fully licensed and approved treatments to patients in need in order to extend and improve their lives. This launch milestone is clear proof of our commitment to that pledge.'
The U.S. Food and Drug Administration approved Artesunate for Injection™ in May, 2020 to treat severe malaria in adults and in children. AMIVAS (US) holds the license.
The European Union Commission awarded approval to AMIVAS Ireland to commercialise Artesunate Amivas in the EU and EEA in late 2021. Approval was granted by the U.K. MHRA in April, 2022.
About Severe Malaria
Malaria is a febrile disease caused by Plasmodium parasites and is usually transmitted by mosquitos. In 2020, almost half of the global population was at risk of contracting it. Over 400,000 deaths are recorded each year from the disease, with sub-Saharan Africa's population being most at risk. In Europe, 50 years after eradication, malaria is still a major health concern. While most infections in Europe are related to international travel, climatic changes are foreseen to enhance the risk for locally transmitted malaria infections in Europe. In Europe, peaks in the number of malaria cases occur July to September. Since the vast majority of malaria cases are imported, this could partly be linked to travellers returning from summer holidays. Malaria can progress to severe malaria, at which point the mortality rate approaches 100 percent if left untreated. Infants and children under five, pregnant women, and people with low immunity are at highest risk of developing severe malaria. Artesunate has been shown to improve survival rates, with particular benefit for patients with high parasitaemia. Complications of severe malaria include severe anaemia and signs of end-organ damage, such as coma (cerebral malaria), lung complications, hypoglycaemia (low glucose blood levels), or acute kidney injury.
Travelers can protect themselves before, during and after travel (https://www.ecdc.europa.eu/en/malaria).
About Artesunate AMIVAS
Intravenous artesunate has been the global standard of care for severe malaria for more than 20 years. Artesunate AMIVAS is approved for the initial treatment of severe malaria in adults and children by the U.S. Food and Drug Administration, the European Medicines Association, and the Medicine and Healthcare Product Regulatory Agency.
Artesunate is associated with up to a 34.7 percent reduction in risk of mortality compared with quinine. Supplied as a sterile powder, Artesunate can be safely stored at room temperature. Artesunate is easily prepared for use in one step.
Artesunate AMIVAS is superior to standard intravenous quinine in the most important clinical parameter, mortality. Artemisinins, the active ingredient in Artesunate AMIVAS, are the fastest-acting clinical anti-malarial compounds. They can be administered intravenously only when formulated to do so.
About AMIVAS
AMIVAS, based in Nassau, Delaware, in the United States, is a post-approval biopharmaceutical company, founded with a mission to improve and extend human lives by discovering, developing, and distributing new best-in-class medicines. AMIVAS responded to the urgent need for a United States- and European-based firm to assume responsibility for regulated manufacture and distribution of Artesunate after quinidine gluconate was discontinued in the U.S. in 2019. The Company achieved U.S. Food and Drug Administration approval for Artesunate for Injection – its first commercial product – in May, 2020. Artesunate for Injection is indicated for the treatment of severe malaria in adults and children. AMIVAS is committed to being the global leader in the battle against infectious diseases, driving scientific discovery and breakthroughs that will redefine the possibilities of critical medicines.
For more information, visit AMIVAS.com and follow AMIVAS on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017001569/en/
Media: Sheila Burke
Methodhealthcomms@gmail.com
+1-484-667-6330
© Business Wire, Inc. Disclaimer:
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
17 hours ago
- Euronews
Brussels, my love? Poles choose 'ordinary man' for President
This week we are joined by Mika Aaltola, a Finnish MEP representing the centre-right European People's Party, Dorota Bawolek, a seasoned EU correspondent for Polish broadcaster TVP and Ian Lesser, Vice President of the German Marshall Fund, the transatlantic think tank. US President Donald Trump's renewed trade offensive has left Brussels rather stressed with sweeping tariffs hitting European steel, aluminium, and car exports — and threats of more to come. European Trade Commissioner Maroš Šefčovič is trying to defuse the crisis, warning that retaliatory EU measures could kick in as early as July 14. MEP Mika Aaltola blasted the US approach as 'unfair treatment'. The OECD also warned this week that Trump's tariffs are dragging global growth to its weakest levels since the COVID-19 pandemic. In a very tight presidential race, Poland elected conservative Karol Nawrocki, a nationalist and eurosceptic, narrowly defeating pro-EU candidate and Warsaw mayor Rafał Trzaskowski. The result marks a blow for Prime Minister Donald Tusk who has called for a vote of confidence in his government early next week. Nawrocki's rhetoric — emphasizing national sovereignty, anti-migrant policies, and a rejection of 'Brussels diktats' — has alarmed Europhiles. However, his nationalist platform resonated with a rather divided electorate. "He's not very presidential", Dorota Bawolek told the panel adding that history shows Poles prefer an 'ordinary guy'. Finally, the panel discuss the Spanish Prime Minister Pedro Sánchez' diplomatic setback after the EU Council rejected his proposal to make Catalan, Basque, and Galician official EU languages. The move, promised to Catalan separatists in exchange for political support, was rejected by member states over fears of a domino effect involving other regional languages. Watch the full episode in the player above. Italians will begin voting on Sunday in a referendum on whether to relax citizenship laws, but there are fears that turnout will be so low that it will invalidate the result. The two-day referendum, ending on Monday, will also ask voters if they agree with reversing a decade-old liberalisation of the labour market. The labour market questions aim to make it more difficult to dismiss some employees and increase compensation for workers who are made redundant by small businesses, reversing a law passed by a Democratic Party (PD) government around a decade ago. But it's the question about citizenship which has attracted the most attention among Italian voters. Concerns about the scale of immigration helped push Prime Minister Giorgia Meloni's far-right Brothers of Italy party to power in 2022. Italians will be asked if they support the idea of reducing the period of residence required to apply for Italian citizenship from 10 years to five. Organisers of the referendum say that, if passed, it could affect around 2.5 million foreign nationals in Italy. Italy's birth rate is in steep decline, and economists say the country needs more foreigners to boost its stagnant economy. For foreigners in Italy, the primary channel to citizenship is through naturalisation, which can occur after 10 years of continuous residence in the country. The applicant must also demonstrate that they have integrated into society, possess a minimum income, have a clean criminal record, and can speak Italian adequately. The residence prerequisite is considerably shorter for citizens of other EU member states, who have to wait just four years to apply. Riccardo Magi, secretary of the liberal Più Europa party, supports decreasing the length of time required to apply for citizenship. He calls the current rules "old and unjust" and says they have only been in force for so long because successive governments have lacked the political will for change. Magi thinks the referendum proposal is reasonable because it only reduces the residence time requirement while leaving the other requirements unchanged. He says the current law "forces hundreds of thousands of girls and boys born or raised in Italy to live as foreigners in what is also their country." Magi also believes the amendment would have indirect positive effects on many of these minors born or resident in Italy, to whom citizenship would be passed on by at least one New Italian parent. "Those are who are rooted, work, pay taxes, study... must be able to vote and participate in public votes. This is the liberal idea of citizenship," he said. But the Noi Moderati party has said its position on the referendum is a resounding no, the centrist party's vice-president Maria Chiara Fazio told Euronews. "Citizenship is the deepest link between the state and the individual," Fazio stressed. "It cannot be the subject of a referendum simplification: it is a topic that requires in-depth study, mutual listening and a serious parliamentary debate." Fazio defended the structure of the current law, but acknowledged some bureaucratic aspects need to be tightened up as they leave many candidates in limbo. But the Noi Moderati's position on the referendum is not unusual. The leaders of two of the coalition parties, Antonio Tajani of Forza Italia and Matteo Salvini of Lega or the League, have both said they will not vote on Sunday. Meloni will attend a polling station but will also not cast a ballot. That indifference to the referendum appears to have trickled down to regular voters too. A Demopolis institute poll carried out in May estimated turnout to be between 31% and 39%, well short of the threshold required to make the result binding.
LeMonde
19 hours ago
- LeMonde
Rare earths: China's magnet war threatens global industry
The problem took a few weeks to show up on production lines. In early April, China imposed restrictions on the export of certain strategic metals – specifically, heavy rare earths and the magnets made from them. This has created a bottleneck for many industries worldwide that depend on these materials. The automotive sector has already begun to feel the impact. Japanese automaker Suzuki was forced to suspend production of its Swift model on May 26 due to a shortage of certain components – rare earth derivatives, according to the business daily Nikkei. At the end of May, Ford halted production of its Explorer SUV for a week after a supplier ran out of magnets made from rare earth alloys. Meanwhile, one of India's leading manufacturers, Bajaj, stated that if nothing changes, the shortage caused by China would "heavily impact" its production of electric vehicles in July. On Wednesday, June 4, the European automotive industry also revealed its exposure to this risk. Without citing specific cases, the European Association of Automotive Suppliers, Clepa, stated that "these restrictions have led to the closure of several production lines and factories in Europe, and the impact will continue to grow in the coming weeks as stocks are depleted." BMW confirmed that some of its suppliers had been affected. "We have shifted to crisis management," said Sylvain Broux, president of the Comité de liaison des industries fournisseurs de l'automobile (CLIFA) in France, while Jean-Louis Pech, president of the Fédération des industries des équipements pour véhicules, described an "economic war in which Europe also has arguments to put forward."
France 24
a day ago
- France 24
EU states look to trim compensation for flight delays
At present, passengers in Europe have a right to between 250 and 600 euros ($285-685) in compensation, depending on flight distance, for delays of three hours or more. But airlines complain that leaves them a hefty bill, and often leads them to cancel flights rather than run them with a long delay, due to knock-on effects on flight schedules. A majority of EU states agreed late Thursday to change the rules, overcoming opposition from Germany in particular, following hours of painstaking negotiations in Luxembourg. Under the new system, the compensation threshold would increase to four hours for flights of up to 3,500 kilometres (2,175 miles), or connecting cities inside the European Union, with its amount set at 300 euros. For longer flights, the right to compensation of 500 euros would kick in after a six-hour delay. The European Consumer Organisation BEUC slammed the plan, saying the "new eligibility thresholds will deprive the majority of passengers from their compensation rights", as most delays are between two and four hours. It urged European lawmakers -- who have yet to approve the text -- to uphold passengers' rights. The compromise did not satisfy airlines either, with the umbrella group Airlines for Europe (A4E) -- which includes Air France-KLM, Lufthansa, Ryanair and easyJet -- complaining that it "introduced even more complexity" than the initial European Commission plan. But a spokesperson for the French aviation industry federation called it a "step forward" for consumers. The rules changes "clarify the law and will avoid many recurrent court disputes," said the spokesperson, Laurent Timset. Poland's infrastructure minister Dariusz Klimczak, whose country currently holds the EU presidency, meanwhile cheered the creation of "over 30 new rights" for passengers, in a statement announcing the deal. Those include a "right to be rerouted" at the earliest opportunity, including through flights operated by other carriers or alternative transport modes. The plan also creates a system for passengers to be automatically compensated for flights cancelled within 14 days of departure. And it spells out the right to assistance -- refreshments, food, accommodation -- when travel is disrupted. France's transport minister Philippe Tabarot declared himself satisfied with the compromise.
